{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T09:25:53Z","timestamp":1760865953718},"reference-count":50,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.clml.2015.11.009","type":"journal-article","created":{"date-parts":[[2015,11,22]],"date-time":"2015-11-22T07:14:16Z","timestamp":1448176456000},"page":"5-11","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Lymphoproliferative Disease and Hepatitis B Reactivation: Challenges in the Era of Rapidly Evolving Targeted Therapy"],"prefix":"10.1016","volume":"16","author":[{"given":"Colin","family":"Phipps","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunxin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daryl","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2015.11.009_bib1","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1128\/JVI.77.1.68-76.2003","article-title":"CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection","volume":"77","author":"Thimme","year":"2003","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.clml.2015.11.009_bib2","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/jmv.1890430210","article-title":"High levels of viral replication during acute hepatitis B infection predict progression to chronicity","volume":"43","author":"Fong","year":"1994","journal-title":"J\u00a0Med Virol"},{"key":"10.1016\/j.clml.2015.11.009_bib3","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1126\/science.284.5415.825","article-title":"Viral clearance without destruction of infected cells during acute HBV infection","volume":"284","author":"Guidotti","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.clml.2015.11.009_bib4","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1586\/17474124.2.2.233","article-title":"Chemokine-directed immune cell infiltration in acute and chronic liver disease","volume":"2","author":"Karlmark","year":"2008","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.clml.2015.11.009_bib5","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0198-8859(02)00753-X","article-title":"Human plasmacytoid\u2013derived dendritic cells and the induction of T-regulatory cells","volume":"63","author":"Gilliet","year":"2002","journal-title":"Hum Immunol"},{"key":"10.1016\/j.clml.2015.11.009_bib6","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/j.1365-2567.2008.02896.x","article-title":"Hepatitis B virus surface antigen impairs myeloid dendritic cell function: a possible immune escape mechanism of hepatitis B virus","volume":"126","author":"Op den Brouw","year":"2009","journal-title":"Immunology"},{"key":"10.1016\/j.clml.2015.11.009_bib7","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1002\/hep.23226","article-title":"Not interferon, but interleukin-6 controls early gene expression in hepatitis B virus infection","volume":"50","author":"Hosel","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.clml.2015.11.009_bib8","doi-asserted-by":"crossref","first-page":"10702","DOI":"10.1128\/JVI.76.21.10702-10707.2002","article-title":"Interleukin-18 inhibits hepatitis B virus replication in the livers of transgenic mice","volume":"76","author":"Kimura","year":"2002","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.clml.2015.11.009_bib9","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.4049\/jimmunol.0903874","article-title":"The hepatitis B virus X protein disrupts innate immunity by downregulating mitochondrial antiviral signaling protein","volume":"185","author":"Wei","year":"2010","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.clml.2015.11.009_bib10","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1128\/JVI.01825-10","article-title":"Hepatitis B virus regulatory HBx protein binds to adaptor protein IPS-1 and inhibits the activation of beta interferon","volume":"85","author":"Kumar","year":"2011","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.clml.2015.11.009_bib11","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jhep.2006.10.007","article-title":"Occult hepatitis B virus infection","volume":"46","author":"Raimondo","year":"2007","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.clml.2015.11.009_bib12","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.jhep.2011.06.006","article-title":"Hepatitis B surface antigen quantification: why and how to use it in 2011\u2014a core group report","volume":"55","author":"Chan","year":"2011","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.clml.2015.11.009_bib13","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0016-5085(75)80054-0","article-title":"Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders","volume":"68","author":"Wands","year":"1975","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clml.2015.11.009_bib14","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/0016-5085(91)90599-G","article-title":"Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study","volume":"100","author":"Lok","year":"1991","journal-title":"Gastroenterology"},{"issue":"suppl 1","key":"10.1016\/j.clml.2015.11.009_bib15","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/annonc\/8.suppl_1.S107","article-title":"Hepatitis B virus carriers in the treatment of malignant lymphoma: an epidemiological study in Japan","volume":"8","author":"Kumagai","year":"1997","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2015.11.009_bib16","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/hep.1840060204","article-title":"Effects of immunosuppressive therapy with prednisolone on B and T lymphocyte function in patients with chronic type B hepatitis","volume":"6","author":"Hanson","year":"1986","journal-title":"Hepatology"},{"key":"10.1016\/j.clml.2015.11.009_bib17","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0016-5085(81)80002-9","article-title":"Effects of immunosuppressive therapy on viral markers in chronic active hepatitis B","volume":"81","author":"Scullard","year":"1981","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clml.2015.11.009_bib18","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0140-6736(80)90442-0","article-title":"Serum levels of hepatitis B surface and core antigens during immunosuppressive treatment of HBsAg-positive chronic active hepatitis","volume":"2","author":"Sagnelli","year":"1980","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2015.11.009_bib19","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/0042-6822(88)90127-4","article-title":"The glucocorticoid receptor recognizes a specific nucleotide sequence in hepatitis B virus DNA causing increased activity of the HBV enhancer","volume":"167","author":"Tur-Kaspa","year":"1988","journal-title":"Virology"},{"key":"10.1016\/j.clml.2015.11.009_bib20","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1053\/jhep.2003.50220","article-title":"Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma","volume":"37","author":"Cheng","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.clml.2015.11.009_bib21","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/cmi.2015.25","article-title":"Reversal of B-cell hyperactivation and functional impairment is associated with HBsAg seroconversion in chronic hepatitis B patients","volume":"12","author":"Xu","year":"2015","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.clml.2015.11.009_bib22","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1056\/NEJM200101043440120","article-title":"Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab","volume":"344","author":"Dervite","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2015.11.009_bib23","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1182\/blood-2003-05-1403","article-title":"Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy","volume":"102","author":"Westhoff","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.11.009_bib24","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1200\/JCO.2008.18.0182","article-title":"Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab","volume":"27","author":"Yeo","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2015.11.009_bib25","doi-asserted-by":"crossref","first-page":"3736","DOI":"10.1200\/JCO.2014.56.7081","article-title":"Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study","volume":"32","author":"Seto","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2015.11.009_bib26","doi-asserted-by":"crossref","first-page":"4769","DOI":"10.1002\/cncr.25253","article-title":"Reactivation of hepatitis B virus after rituximab-containing treatment in patients with CD20-positive B-cell lymphoma","volume":"116","author":"Matsue","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2015.11.009_bib27","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1002\/hep.26718","article-title":"Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study","volume":"59","author":"Hsu","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.clml.2015.11.009_bib28","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/j.1600-0609.2004.00375.x","article-title":"Hepatitis B virus reactivation and alemtuzumab therapy","volume":"74","author":"Iannitto","year":"2005","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2015.11.009_bib29","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jcv.2005.10.009","article-title":"Adefovir added to lamivudine for hepatitis B recurrent infection in refractory B-cell chronic lymphocytic leukemia on prolonged therapy with Campath-1H","volume":"35","author":"Cortelezzi","year":"2006","journal-title":"J\u00a0Clin Virol"},{"key":"10.1016\/j.clml.2015.11.009_bib30","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/jmv.20705","article-title":"Lamivudine prophylaxis and treatment of hepatitis B virus\u2013exposed recipients receiving reduced intensity conditioning hematopoietic stem cell transplants with alemtuzumab","volume":"78","author":"Moses","year":"2006","journal-title":"J\u00a0Med Virol"},{"key":"10.1016\/j.clml.2015.11.009_bib31","doi-asserted-by":"crossref","unstructured":"Ifuku H, Kusumoto S, Tanaka Y, et\u00a0al. Fatal reactivation of hepatitis B virus infection in a patient with adult T-cell leukemia\u2013lymphoma receiving the anti-CC chemokine receptor 4 antibody mogamulizumab. Hepatol Res E pub 15 April 2015","DOI":"10.1111\/hepr.12513"},{"key":"10.1016\/j.clml.2015.11.009_bib32","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/hepr.12117","article-title":"Reactivation of hepatitis B virus in a patient with adult T-cell leukemia-lymphoma receiving the anti-CC chemokine receptor 4 antibody mogamulizumab","volume":"44","author":"Nakano","year":"2014","journal-title":"Hepatol Res"},{"key":"10.1016\/j.clml.2015.11.009_bib33","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s12185-015-1750-z","article-title":"Reactivation of hepatitis B virus (HBV) infection in adult T-cell leukemia\u2013lymphoma patients with resolved HBV infection following systemic chemotherapy","volume":"101","author":"Totani","year":"2015","journal-title":"Int J Hematol"},{"key":"10.1016\/j.clml.2015.11.009_bib34","first-page":"949","article-title":"[Hepatitis B virus reactivation induced by brentuximab vedotin in the treatment of Hodgkin lymphoma: a case report and literature review]","volume":"35","author":"Yang","year":"2014","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"10.1016\/j.clml.2015.11.009_bib35","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.3109\/10428194.2014.941833","article-title":"Hepatitis B virus reactivation in patients with multiple myeloma receiving bortezomib-containing regimens followed by autologous stem cell transplant","volume":"56","author":"Li","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2015.11.009_bib36","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S1665-2681(19)30855-5","article-title":"Hepatitis B reactivation in patients with multiple myeloma and isolated positive hepatitis B core antibody: a call for greater cognizance","volume":"13","author":"Yang","year":"2014","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.clml.2015.11.009_bib37","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1053\/j.gastro.2006.01.001","article-title":"Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones","volume":"130","author":"Pollicino","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clml.2015.11.009_bib38","doi-asserted-by":"crossref","first-page":"5798","DOI":"10.1073\/pnas.94.11.5798","article-title":"Reactivation of silenced, virally transduced genes by inhibitors of histone deacetylase","volume":"94","author":"Chen","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clml.2015.11.009_bib39","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.3324\/haematol.2009.008607","article-title":"Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy: a case series report","volume":"94","author":"Ritchie","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2015.11.009_bib40","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hep.23190","article-title":"Chronic hepatitis B: update 2009","volume":"50","author":"Lok","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.clml.2015.11.009_bib41","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1200\/JCO.2015.61.3745","article-title":"Hepatitis B virus screening for patients with cancer before therapy: American Society of Clinical Oncology provisional clinical opinion update","volume":"33","author":"Hwang","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2015.11.009_bib42","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1053\/j.gastro.2014.10.038","article-title":"American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy","volume":"148","author":"Perrillo","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clml.2015.11.009_bib43","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2012.02.010","article-title":"EASL clinical practice guidelines: management of chronic hepatitis B virus infection","volume":"57","year":"2012","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.clml.2015.11.009_bib44","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1053\/j.gastro.2003.09.026","article-title":"Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy","volume":"125","author":"Lau","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clml.2015.11.009_bib45","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1002\/hep.22106","article-title":"A\u00a0revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial","volume":"47","author":"Hsu","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.clml.2015.11.009_bib46","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","article-title":"Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study","volume":"381","author":"Marcellin","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2015.11.009_bib47","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1002\/hep.22841","article-title":"Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy","volume":"49","author":"Tenney","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.clml.2015.11.009_bib48","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1001\/jama.2014.15704","article-title":"Entecavir vs. lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial","volume":"312","author":"Huang","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.clml.2015.11.009_bib49","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nrgastro.2013.216","article-title":"Management of patients with hepatitis B who require immunosuppressive therapy","volume":"11","author":"Hwang","year":"2014","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.clml.2015.11.009_bib50","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1200\/JCO.2012.48.5938","article-title":"Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B","volume":"31","author":"Huang","year":"2013","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265015013798?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265015013798?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,11]],"date-time":"2020-09-11T18:00:03Z","timestamp":1599847203000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265015013798"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["S2152265015013798"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2015.11.009","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lymphoproliferative Disease and Hepatitis B Reactivation: Challenges in the Era of Rapidly Evolving Targeted Therapy","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2015.11.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}